Navigation Links
Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform
Date:11/4/2009

CLARKSVILLE, Md., Nov. 4 /PRNewswire/ -- Neuronascent, Inc., a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer's disease, Parkinson's and other neurodegenerative diseases, announces it has entered into a discovery agreement with ChemRar Pharma, a Russian biotechnology start-up company focusing on small-molecule modulators for developmental pathways and stem cells to treat cancer. Under the terms of the agreement, Neuronascent will screen certain ChemRar proprietary developmental pathway inhibitors utilizing their proprietary drug discovery platform for neurogenesis and neuroprotection. Financial terms of the collaboration were not disclosed.

The agreement matches ChemRar's discovery and translational research focus through scientific collaboration with Neuronascent's success in discovering novel, neurogenic and neuroprotective drug candidates. The companies intend to evaluate co-development opportunities for future commercialization and funding.

"We are proud to start this collaboration with ChemRar Pharma on these studies, highlighting our expertise in the field of neurogenesis, and look forward to the potential of this relationship," notes Dr. Judith Kelleher-Andersson, President and CSO, Neuronascent, Inc.

Nikolay Merkin, CBO of ChemRar Pharma, comments: "We are pleased that Neuronascent will bring high value to our R&D program and expand the scope of our molecules with their unique and well-established stem cell and neurogenesis platform. We look forward to achieving success in this collaboration."

About ChemRar Pharma:

ChemRar Pharma was established in 2007 in Moscow, Russia under the roof of the ChemRar High Tech Center as an innovative oncology start-up. In 2009, ChemRar in-licensed the portfolio of developmental pathway inhibitors from AllaChem and ChemDiv, Inc. (San Diego, CA) and established the R&D collaboration with ChemDiv's Chemical Diversity Research Institute in Moscow to continue preclinical and clinical development for multiple cancer indications.

About Neuronascent, Inc.:

Founded in 2004 by Dr. Judith Kelleher-Andersson, Neuronascent, Inc. discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, neurodegenerative diseases, including Alzheimer's and Parkinson's, and Down syndrome. The Company is headquartered in Clarksville, MD and has facilities in Rockville and Walkersville, MD. For additional information, please visit www.neuronascent.com.

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects" and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ moderately from current expectations.

SOURCE Neuronascent, Inc.


'/>"/>
SOURCE Neuronascent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
2. BD Announces Results for Fourth Fiscal Quarter and Full Year
3. WebMD Health Corp. Announces Intention To Commence Tender Offer To Repurchase Up To 5,700,000 Shares of its Common Stock
4. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Industrial Conference
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
6. West Announces Third Quarter 2009 Results
7. Rigel Announces Third Quarter 2009 Financial Results
8. VIVUS Announces Promotion of Peter Tam to President
9. ATS Medical Announces Third Quarter 2009 Results
10. BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
11. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD is pleased to announce ... shares for trading on the TSX Venture Exchange.  ... TSXV follows a year of significant achievements for Invictus-MD. ... successful test crops at AB Laboratories Inc. ("AB Labs"), ...
(Date:3/27/2017)... 2017 On Friday, benchmark US ... closed the trading session up 0.19%; the Dow Jones ... was down 0.08%. US markets made broad based gains ... in green. Pre-market today, Stock-Callers.com reviews these four Medical ... WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... in their profession as their value increases in the healthcare workforce, according to ... such as job boards, career fairs, and candidate leads to healthcare employers of ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Bacteria and fungi are probably not the first ... bad. In fact, including the right microorganisms in your diet can actually improve health outcomes. ... , This is the topic of a new peer-reviewed paper led by ...
(Date:3/27/2017)... ... March 27, 2017 , ... The respected dental team at ... teeth without the extensive time commitment and aesthetic disadvantages of traditional braces can ... A custom-designed series of virtually invisible aligners are created for each patient and ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want ... their missing teeth can now have them placed by Dr. Manju Kejriwal, with or ... Cone Beam technology to increase the accuracy of each dental implant placement. The i-CAT ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):